SCHEDULE: LakeShore Biopharma Take-Private Bid at $0.86/Share

A consortium including major shareholders proposes to acquire all outstanding shares of LakeShore Biopharma Co., Ltd for $0.86 per share in cash, aiming to take the company private.

Summary

• A consortium comprising Huaqin Xue, Crystal Peak Holdings Inc., Crystal Peak Investment Inc., Dave Liguang Chenn, Oceanpine Investment Fund II LP, and Oceanpine Capital Inc. has proposed to acquire all outstanding ordinary shares of LakeShore Biopharma Co., Ltd not currently owned by them.
• The non-binding proposal offers US$0.86 in cash per ordinary share.
• The consortium collectively beneficially owns 21,484,092 ordinary shares, representing approximately 52.1% of the 41,212,693 outstanding ordinary shares as of June 30, 2025.
• The acquisition of the publicly held shares is estimated to cost approximately US$20,000,000, to be funded by equity capital arranged by the Reporting Persons.
• Existing shareholder Reporting Persons intend to roll over their equity interests into an acquisition vehicle.
• The proposed transaction is not expected to be subject to a financing condition.
• If consummated, LakeShore Biopharma's ordinary shares would be delisted from NASDAQ and its registration terminated, making it a privately held company.

Sentiment

Score: 7

Explanation: The filing outlines a clear, structured, and well-funded proposal for a take-private transaction by a consortium of major shareholders. While non-binding, the exclusivity agreement and commitment to roll over equity suggest a high likelihood of progression. The offer provides a potential liquidity event for public shareholders, though at the cost of future public market participation.

Positives

• Public shareholders are offered a cash price of US$0.86 per share, potentially providing liquidity and a premium over the current market price.
• The proposal is not expected to be subject to a financing condition, which reduces a common risk factor in take-private transactions.
• The consortium, holding over 50% of outstanding shares, demonstrates strong alignment and commitment to the transaction through a formal Consortium Agreement.

Negatives

• The proposal is preliminary and non-binding, meaning there is no guarantee the transaction will be completed.
• If the transaction is consummated, LakeShore Biopharma's shares would be delisted from NASDAQ, removing public trading access for investors.
• Shareholders would lose the potential for future appreciation if the company's value were to increase significantly as a private entity.

Risks

• The proposal is non-binding and subject to negotiation and execution of definitive agreements, which may not be reached.
• There is no assurance that the Proposed Transaction or any other transaction will be approved or consummated.
• The transaction could be terminated, or its terms could change.
• The delisting of shares would remove liquidity for public shareholders.

Future Outlook

The consortium intends to take LakeShore Biopharma Co., Ltd private, which would result in the delisting of its ordinary shares from NASDAQ and termination of its SEC registration. The transaction is expected to lead to a change in the company's corporate structure and board of directors, with the company becoming a privately held entity.

Management Comments

• The Proposal indicates that it is Oceanpine's preliminary indication of interest, and does not constitute any binding commitment with respect to the transactions proposed under the Proposal or any other transaction.
• No agreement, arrangement or understanding between the Issuer and Oceanpine relating to any proposed transaction will be created until such time as definitive documentation has been executed and delivered by Oceanpine and the Issuer and all other appropriate parties.
• Each Consortium Member shall work exclusively with each other to implement the Proposed Transaction... and vote... in favor of the Proposed Transaction, and not to acquire or dispose of the Ordinary Shares of the Issuer, subject to certain exceptions.
• Neither the Issuer nor any Consortium Member is obligated to complete the Proposed Transaction, and a binding commitment with respect to the Proposed Transaction will result only from the execution of definitive documents, and then will be on the terms provided in such documentation.

Industry Context

This take-private proposal for LakeShore Biopharma Co., Ltd reflects a broader trend of private equity and strategic investors seeking to acquire public companies, particularly in specialized sectors like biopharma, to pursue long-term strategies away from public market scrutiny. Such transactions often occur when public market valuations are perceived as undervalued or when significant restructuring or investment is required that is better managed in a private setting. The involvement of a consortium, including existing major shareholders, is common in these types of transactions, as it consolidates control and simplifies the acquisition process.

Comparison to Industry Standards

• This filing details a non-binding take-private proposal, not operational results, so direct comparison to industry operational benchmarks is not applicable.
• The offer price of US$0.86 per share would need to be evaluated against the company's historical trading prices, analyst price targets, and valuations of comparable biopharma companies that have recently gone private or been acquired.
• Without specific market data for LakeShore Biopharma or details on its financial performance, it is difficult to assess if the offer price represents a standard premium for such a transaction in the biopharma sector. Typically, take-private offers include a premium over the pre-announcement trading price to incentivize public shareholders.

Corporate Governance

Related Party Transactions

• The formation of a "Consortium" among existing significant shareholders (Huaqin Xue, Crystal Peak entities, Oceanpine entities) to jointly propose a take-private transaction.
• The Consortium Agreement includes provisions for exclusive cooperation, voting agreements, and equity rollovers, which are arrangements between related parties.

Stakeholder Impact

• Shareholders: Public shareholders would receive US$0.86 per share in cash, providing liquidity but ending their investment in a publicly traded entity. Consortium members would roll over their equity into a private vehicle.
• Employees: No direct impact on employees is mentioned, but a take-private transaction can sometimes lead to operational restructuring.
• Customers/Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned, but the financing structure of the take-private could affect the company's capital structure.

Next Steps

• Negotiation and execution of definitive agreements between the Issuer's special committee (or board) and the Consortium.
• Cooperation among Consortium members in engaging advisors and finalizing agreements.
• Consortium members to vote their equity securities in favor of the Proposed Transaction and against any alternative transactions.
• Contribution of cash or ordinary shares by applicable Consortium members to a new company in exchange for equity interests, subject to definitive agreements.
• If consummated, delisting of LakeShore Biopharma's ordinary shares from NASDAQ and termination of SEC registration.

Key Dates

Recommendation

The filing presents a non-binding take-private proposal at a specific cash price of US$0.86 per share. Given that the consortium includes major shareholders and has entered into an exclusivity agreement, the probability of the transaction moving forward is significant. For existing shareholders, holding the stock to realize the potential cash offer is a reasonable strategy, assuming the current market price is below or near the offer. However, the non-binding nature means there's no guarantee, and the offer price could be subject to negotiation. A "hold" recommendation reflects the potential for the offer to materialize while acknowledging the inherent uncertainties of a non-binding proposal. There is no information to suggest a "buy" (unless the stock is trading significantly below $0.86 and the deal is highly likely) or "sell" (unless one believes the deal will fall through or a higher offer is unlikely).

Keywords

LakeShore Biopharma, take-private, Schedule 13D, beneficial ownership, ordinary shares, NASDAQ delisting, private equity, Oceanpine, Crystal Peak, Huaqin Xue, Dave Liguang Chenn, going private, M&A